New combo therapy aims to halt lung scarring in scleroderma
NCT ID NCT07491523
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is for people with scleroderma who also have lung scarring (interstitial lung disease). It compares two treatments: a double immunosuppression regimen (rituximab plus mycophenolate mofetil) versus the same double therapy plus an anti-fibrotic drug (nintedanib or pirfenidone). The goal is to see if adding the anti-fibrotic better preserves lung function over one year. About 35 participants will be followed with regular breathing tests.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rituximab, mycophenolate mofetil, and either nintedanib or pirfenidone
What this could lead to
If it works, this could point toward a better treatment combination to slow lung damage in people with scleroderma-related lung disease.
What could go wrong
This is a small, early-phase study with only 35 participants, so results may not apply to everyone. Adding an anti-fibrotic drug may also increase side effects like stomach issues or fatigue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SSC-SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of patras
RECRUITINGPátrai, Greece
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact